Medical Device News

Ovarian Cancer Surgery: Birmingham Research Informs New Guidance

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Patients with advanced ovarian cancer are now being recommended surgery that the University of Birmingham researchers have found leads to better outcomes.

The National Institute of Clinical Excellence (NICE) today has published new guidance about the use of maximal cytoreductive surgery following a consultation on evidence including research from Professor Sudha Sundar and colleagues from the University’s Institute of Cancer and Genomic Sciences for the SOCQER-2 trial published in BJOG: an International Journal of Obstetrics & Gynaecology and Cancers

Among the key pieces of research consulted on, Professor Sundar’s research conducted between the Institutes of Cancer and Genomic Sciences and Applied Health Research showed that women treated in centres where this kind of surgery is routinely conducted, (which involves operating on a number of organs and can include removal of part of the breathing muscle and bowel) had six months increased overall survival rates compared to those that only conducted less extensive surgery.

Put differently, women with late-stage ovarian cancer treated at centres that routinely conduct maximal cytoreduction surgery have a 20% reduction in their chance of dying from ovarian cancer.

The research further found that quality of life in women was the same after 12 months regardless of whether women underwent maximal cytoreductive surgery or less extensive surgery

Sudha Sundar, Professor of Gynaecological Cancer at the University of Birmingham commented: “Ovarian cancer is a huge burden affecting women across the UK. Anything that improves survival rates and quality of life for women is significant. Increasing the time that women can spend with those they love after a late-stage diagnosis has a profoundly positive impact and is something that I am immensely proud to have contributed to.

“The SOCQER-2 trial has shown that this major surgery to fully remove all traces of cancer, despite the seemingly high levels of impact on women’s lives afterwards, made a significant difference to their quality of life as well as increasing survival time after surgery.”

NICE’s new guidelines on maximal cytoreductive surgery –

Medical Device News Magazine
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Ultrahuman Announces its App Store ‘PowerPlugs’ with the World’s First AFib Detection Technology on a Smart Ring

Recognizing each individual’s health journey is unique, PowerPlugs enable people to choose and focus on the aspects of their health that matter most. It’s designed for highly personalized health insights, ensuring that every individual can personalize their health tracking to their unique needs and goals.

VisionAir Solutions Celebrates Milestone and New Collaboration

This achievement marks VisionAir Solutions commitment to bringing technological innovation to pulmonary medicine. Since its acquisition by Theken Companies last year, VAS has over doubled its growth and continues to demonstrate industry adoption and the advantages of personalized healthcare.

Valencia Technologies Announces CMS Publication of 2025 Medicare Proposed Rule for eCoin® Procedure

Ann Decker, VP of Reimbursement for Valencia Technologies, stated, "The cumulative effect of the proposed 2025 continuation of APC assignment 5464, the improved ASC payment rate, and the recognition of ITNS as a minimally invasive OAB treatment option in the recently updated guidelines by the American Urological Association (AUA) and the Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU), underscores that the eCoin ITNS system will have a strong reimbursement pathway throughout 2025 and beyond.